Safety/Efficacy of a Pusher, Thermal Detachment Coil for Ruptured Intracranial Aneurysms: A Multicenter Real-World Study

推入式热脱位弹簧圈治疗破裂性颅内动脉瘤的安全性和有效性:一项多中心真实世界研究

阅读:1

Abstract

BACKGROUND AND PURPOSE: Optima coils are a new type of embolic coils with complex and WAVE shape properties and variable degrees of softness. In patients with ruptured intracranial aneurysms, we examined the safety (periprocedural complications) and efficacy (occlusion rate immediately postprocedure) of the Optima coil. METHODS: We studied 103 consecutive patients with ruptured intracranial aneurysms who were treated exclusively with the Optima coil, without the use of accompanying implanted devices, at five centers in Spain. Endovascular techniques included stand-alone or balloon-assisted coiling. Postprocedural occlusion and periprocedural device-related adverse events were the endpoints. Aneurysm occlusion was graded according to the modified Raymond-Roy Occlusion scale. RESULTS: Of the 103 enrolled patients (70 female; median age 59 years), 59 (57.3%) presented with an IV Fischer Scale grade, and 61 (59.2%) of the ruptured aneurysms were wide-necked. Thirty-eight (36.9%) aneurysms were located in the anterior communicating artery. Simple-coiling and balloon-assisted coiling were performed in 36 (34.9%) and 65 (63.1%) patients, respectively. Raymond-Roy Class I, II, and III were reached in 64 (60.3%), 29 (28.1%), and ten (9.7%) following the procedure. The periprocedural device-related serious adverse event rate was 12 (13.5%), of which eight (7.7%) were due to coil protrusion. Four (3.8%) patients had intraprocedural aneurysm rupture. No early rebleeding or death was reported. CONCLUSION: This analysis suggests that the Optima coil is safe and effective for treating ruptured aneurysms, with satisfactory occlusion rates and low rates of periprocedural device-related serious adverse events.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。